BioSpace News Archive

Acquisition will expand Ambulatory Remote Cardiac ECG Monitoring product technology offering and outreach into US and international markets

IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing, announced today the election of Dr. Asha S. Collins , Head of U.S. Clinical Operations of Genentech, a biotechnology company and member of the Roche Group, to the Company’s Board of

Plan to advance AXA1125 directly into a Phase 2b biopsy clinical trial in NASH under IND following successful Type B pre-IND meeting with FDA Plan to advance AXA1665 directly into a Phase 2 clinical trial in OHE under IND following positive top-line data from AXA1665-002 Published peer-reviewed manuscripts highlighting therapeutic benefit of EMMs and results from AXA1665-001 clinical study

Bioceres Crop Solutions Corp., a fully-integrated provider of crop productivity solutions designed to enable the transition of agriculture towards carbon neutrality, announced that it has entered into definitive agreements for the acquisition of the remaining 50% ownership interest in Verdeca LLC as well as strategic Intellectual Property assets related to soybean and wheat from Arcadia Biosciences Inc.

Dynatronics Corporation (NASDAQ : DYNT), a leading manufacturer of athletic training, physical therapy, and rehabilitation products, today announced financial results for its first quarter of fiscal year 2021.

Publication Explores the Beneficial Effects of Apabetalone on the Immune Cells of Diabetic Patients Event Reminder: Multiple Presentations on Apabetalone to be made during the American Heart Association Scientific Sessions

Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that its Belgian subsidiary Aligos Belgium BV has been awarded a €1.8M grant by the Flemish Agency for Innovation and Entrepreneurship (VLAIO) to support a nonclinical research project related to combination thera

- Company nominates OPA1 as the next preclinical target for its proprietary TANGO approach to treating the underlying cause of severe genetic diseases – - OPA1 protein deficiency is the leading cause of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder –

Harmony Biosciences Holdings, Inc. (“Harmony”) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today reported financial results for the quarter ended September 30, 2020

Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, today reported financial results for its fiscal second quarter and six months ended September 30, 2020. Immunovant ended the quarter with approximately $444 million in cash. “Our team made outstanding operational and strategic progress during the fiscal second quarter,” said Pete Salzmann, M.D., Chief